6-in-1 Pediatric Vaccine Launched in India
Hexaxim delivers protection against diphtheria, tetanus, pertussis, polio, Haemophilus influenza B and Hepatitis B
Sanofi Pasteur launched its ready-to-use fully liquid six-in-one vaccine designed to protect infants against six diseases, including polio.
The innovative vaccine can help reduce administration time and the number of injections that children receive.
The vaccine, Hexaxim indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age.
Hexaxim delivers protection against six major childhood diseases -- diphtheria, tetanus, pertussis (whooping cough), polio, Haemophilus influenza B and Hepatitis B.
"We are very excited and proud to introduce India's first six-in-one combination pediatric vaccine," Jean-Pierre Baylet, Country Head - Sanofi Pasteur India, Nepal and Sri Lanka.
Hexaxim today protects infants in more than 60 countries, with over 20 million doses distributed worldwide, Sanofi Pasteur said.
“A 6 in 1 pediatric vaccine reduces the number of vaccination visits for infants. It is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against 6 major childhood diseases,” said Dr Pio Lopez, Pediatrician, Infectologist, Professor at the Universidad del Valle in Cali and President of the Vaccines Chapter of the Colombian Association of Infectious Diseases (ACIN), and principal investigator for a clinical study of the vaccine in Colombia.
“Hexaxim also includes inactivated poliovirus vaccine which is an important step to ensure communities remain polio-free.”
Key benefits of the Hexaxim vaccine:
- Hexaxim is a fully liquid, ready to use vaccine; no reconstitution is needed prior to administration which improves convenience for healthcare professionals. It is available in vial and/or syringe presentations.
- By combining six vaccines into one, Hexaxim reduces the number of injections, which improves comfort and vaccination compliance for infants.
- The use of acP (acellular pertussis) antigens and IPV (inactivated poliovirus vaccine), both commonly used in North America and Europe, improves safety and reduces reactogenicity as compared to wcP (whole cell pertussis)-containing vaccines and OPV (oral polio vaccine).
During its clinical study assessment, Hexaxim was found to be safe and well tolerated as a primary series and booster vaccination in all schedules, countries, and ethnicities tested, it added.